Myriad Pharmaceuticals, Inc. Confirms That MPC-3100, a Fully-Synthetic Hsp90 Inhibitor, is Orally-Bioavailable in Patients in Phase 1 Studies

SALT LAKE CITY, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preliminary phase 1 data for MPC-3100, its fully-synthetic small molecule Hsp90 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.